Research programme: cardiosphere-derived stem cell therapeutics - Capricor Therapeutics
Alternative Names: CDC therapeutics - Capricor; CPI-002; CPI-004; CPI-005Latest Information Update: 28 Nov 2019
At a glance
- Originator Capricor
- Developer Capricor Therapeutics; Cedars-Sinai Health System; Johns Hopkins University School of Medicine
- Class Cell therapies; Exosome therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic heart failure; Myocardial infarction
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Chronic-heart-failure in USA (Intracoronary, Infusion)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Myocardial-infarction in USA (Intracardiac, Injection)
- 11 Nov 2017 Cardiosphere-derived stem cell therapeutics is still undergoing preclinical development for Chronic heart failure and Myocardial infarction in USA